LGN vs NBIX · rev $2.55B vs P/E 45, rev $1.77B
Legence Corp. Class A Common stock (LGN) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Legence Corp. Class A Common stock (LGN) is a engineering & construction company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LGN revenue for 2025-12-31 was $2.55B. Net income was -$59.8M. Revenue was up 21.5% from 2024-12-31 to 2025-12-31. LGN currently screens at market cap $14.66B.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
LGN currently screens at market cap $14.66B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the LGN and NBIX stock pages for the full models.
Not investment advice.